<DOC>
	<DOCNO>NCT00653757</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray kill tumor cell . Using scintigraphy plan specialize radiation therapy delivers high dose radiation directly tumor may kill tumor cell cause less damage normal tissue . PURPOSE : This phase I/II trial study side effect best way give intensity-modulated radiation therapy see well work treat patient stage I , stage II , stage III , stage IV prostate cancer .</brief_summary>
	<brief_title>Intensity-Modulated Radiation Therapy Treating Patients With Stage I , Stage II , Stage III , Stage IV Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To assess feasibility radioimmunoguided intensity-modulated radiotherapy ( IMRT ) stage I-IV prostate cancer . - To determine toxicity tolerance regimen patient . - To determine tumor response base physical examination serial measurement serum prostate-specific antigen ( PSA ) level patient . - To determine outcome patient treat study radioimmunoguided IMRT compare 2 control group patient treat Mayo Scottsdale Clinic ( MSC ) . OUTLINE : Patients undergo radioimmunoguided intensity-modulated radiotherapy daily , 5 day week 8½ week . Beginning last week radiotherapy , patient receive leuprolide acetate intramuscularly every 3-4 month goserelin subcutaneously every 3 month 6 month , 12 month , disease progression . After completion study treatment , patient follow every 3-4 month 1 year , every 6 month 4 year annually thereafter</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Pathologically confirm prostate cancer Stage IIV disease ( T14 , N01 , M0 ) No evidence distant metastasis ( M0 ) physical examination bone scan PATIENT CHARACTERISTICS : ECOG performance status 02 Hemoglobin ≥ 10.0 g/dL WBC ≥ 3,000/mcL Platelet count ≥ 90,000/mm AST &lt; 2 time upper limit normal No allergy leuprolide acetate goserelin PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage II prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>